Dolutegravir 50mg / Lamivudine 300mg tablets
NHS hospitals in England used £184,994,215 of indicative cost of Dolutegravir 50mg / Lamivudine 300mg tablets in the 12 months to July 2026, about 0.7% of all hospital medicines spend. That is up 29.0% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Dolutegravir 50mg / Lamivudine 300mg tablets: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to July 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Dolutegravir 50mg / Lamivudine 300mg tablets most
By indicative cost over the 12 months to July 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| Chelsea & Westminster Hospital Nhs Ft | £22,771,112 |
| Royal Free London Nhs Foundation Trust | £11,949,296 |
| Manchester University Nhs Ft | £8,580,145 |
| University College London Foundation Tr | £7,136,882 |
| Ctrl & N W London Nhs Foundation Trust | £6,407,927 |
| Aintree University Hospital Nhs Ft | £5,988,646 |
| University Hpls Of Leicester Nhs Trust | £5,748,434 |
| Univ Hpl B/Ham Nhs Foundation Trust | £5,700,680 |
| North Bristol Nhs Trust | £5,100,883 |
| Barts Health Nhs Trust | £5,097,818 |
The primary-care picture
Dolutegravir is also dispensed in the community. See the national primary-care prescribing volume, cost and trend on the Dolutegravir medicine page.